Douglas R. Fullen

8.9k total citations · 1 hit paper
130 papers, 5.5k citations indexed

About

Douglas R. Fullen is a scholar working on Oncology, Molecular Biology and Dermatology. According to data from OpenAlex, Douglas R. Fullen has authored 130 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Oncology, 35 papers in Molecular Biology and 35 papers in Dermatology. Recurrent topics in Douglas R. Fullen's work include Cutaneous Melanoma Detection and Management (37 papers), Polyomavirus and related diseases (20 papers) and Melanoma and MAPK Pathways (16 papers). Douglas R. Fullen is often cited by papers focused on Cutaneous Melanoma Detection and Management (37 papers), Polyomavirus and related diseases (20 papers) and Melanoma and MAPK Pathways (16 papers). Douglas R. Fullen collaborates with scholars based in United States, Australia and India. Douglas R. Fullen's co-authors include Timothy M. Johnson, Mark Shackleton, Sean J. Morrison, Elsa Quintana, Michael S. Sabel, Lori Lowe, Lyndon D. Su, Paul W. Harms, Stephen B. Gruber and Hannah R. Foster and has published in prestigious journals such as Nature, Journal of Clinical Oncology and Nature Cell Biology.

In The Last Decade

Douglas R. Fullen

123 papers receiving 5.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficient tumour formation by single human melanoma cells

2008 1.3k citations Elsa Quintana, Mark Shackleton et al. profile →

Peers

Countries citing papers authored by Douglas R. Fullen

Since Specialization

Citations

This map shows the geographic impact of Douglas R. Fullen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas R. Fullen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas R. Fullen more than expected).

Fields of papers citing papers by Douglas R. Fullen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas R. Fullen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas R. Fullen. The network helps show where Douglas R. Fullen may publish in the future.

Co-authorship network of co-authors of Douglas R. Fullen

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas R. Fullen. A scholar is included among the top collaborators of Douglas R. Fullen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas R. Fullen. Douglas R. Fullen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Role of single‐nucleotide polymorphism microarray in the classification of BAP1‐inactivated melanocytic tumours 2025 ·Histopathology ·Joseph S. Durgin, (unknown), (unknown), Douglas R. Fullen, Alexandra C. Hristov, Lori Lowe, Rajiv M. Patel, Paul W. Harms, Aleodor A. Andea, Scott C. Bresler	1
2	Utility of GLI1 RNA Chromogenic in Situ Hybridization in Distinguishing Basal Cell Carcinoma From Histopathologic Mimics 2023 ·Modern Pathology ·Tyler D. Menge, Joseph S. Durgin, Steven Hrycaj, (unknown), Rajiv M. Patel, Paul W. Harms, Douglas R. Fullen, May P. Chan, Scott C. Bresler	1
3	Polypoid melanoma is associated with aggressive histopathological characteristics and poor clinical prognosis: A retrospective cohort study 2022 ·Journal of the American Academy of Dermatology ·Elisabeth A. Pedersen, Paul W. Harms, Lili Zhao, Aleodor A. Andea, Douglas R. Fullen, Lori Lowe, May P. Chan, Rajiv M. Patel, Alison B. Durham	0
4	Primary cutaneous malignant perivascular epithelioid cell tumor: Case of a rare tumor with review of the literature 2021 ·Journal of Cutaneous Pathology ·(unknown), Tyler D. Menge, (unknown), Scott C. Bresler, Rajiv M. Patel, Douglas R. Fullen, (unknown)	7
5	Immunophenotypic switch in cutaneous T‐cell lymphoma: A series of three cases and review of the literature 2021 ·Journal of Cutaneous Pathology ·(unknown), Grace A. Hile, Noah A. Brown, Douglas R. Fullen, Lori Lowe, Trilokraj Tejasvi, Ryan A. Wilcox, Paul W. Harms, May P. Chan, Scott C. Bresler, Alexandra C. Hristov	6
6	Ethical and professionalism issues in dermatopathology: A cross‐sectional survey of American Society of Dermatopathology Members 2020 ·Journal of Cutaneous Pathology ·(unknown), Howa Yeung, (unknown), Jill Allbritton, Bijal Amin, (unknown), Douglas R. Fullen, Robert E. LeBlanc, Beth S. Ruben, John T. Seykora, (unknown), Benjamin K. Stoff	1
7	DNA copy number changes correlate with clinical behavior in melanocytic neoplasms: proposal of an algorithmic approach 2020 ·Modern Pathology ·Ahmed Al‐Omari, (unknown), Michael D. Carter, Paul W. Harms, Lori Lowe, Alison B. Durham, Douglas R. Fullen, Rajiv M. Patel, Alexandra C. Hristov, May P. Chan, Min Wang, Aleodor A. Andea	21
8	Adult-onset hydroa vacciniforme-like lymphoma in a long-term resident of the United States 2018 ·JAAD Case Reports ·(unknown), Lauren E. Franzblau, Douglas R. Fullen, Shannon A. Carty, Trilokraj Tejasvi	2
9	Age and Gender Associations of Virus Positivity in Merkel Cell Carcinoma Characterized Using a Novel RNA In Situ Hybridization Assay 2017 ·Clinical Cancer Research ·Lisha Wang, Paul W. Harms, Nallasivam Palanisamy, Shannon Carskadon, Xuhong Cao, Javed Siddiqui, Rajiv M. Patel, Sylvia Zelenka-Wang, Alison B. Durham, Douglas R. Fullen, Kelly L. Harms, Fengyun Su, Sudhanshu Shukla, Rohit Mehra, Arul M. Chinnaiyan	26
10	Comprehensive histopathological comparison of epidermotropic/dermal metastatic melanoma and primary nodular melanoma 2017 ·Histopathology ·Stephanie L. Skala, David Arps, Lili Zhao, (unknown), Min Wang, Paul W. Harms, Aleodor A. Andea, Douglas R. Fullen, May P. Chan	10
11	Gynecologic melanomas: A clinicopathologic and molecular analysis 2017 ·Gynecologic Oncology ·Aaron M. Udager, (unknown), Linda Hong, Marina Stasenko, Carolyn M. Johnston, J. Rebecca Liu, May P. Chan, Paul W. Harms, Douglas R. Fullen, (unknown), Dafydd G. Thomas, Lori Lowe, Rajiv M. Patel	26
12	Next generation sequencing of Cytokeratin 20-negative Merkel cell carcinoma reveals ultraviolet-signature mutations and recurrent TP53 and RB1 inactivation 2016 ·Modern Pathology ·Paul W. Harms, Angela M. B. Collie, Daniel H. Hovelson, Andi K. Cani, Monique Verhaegen, Rajiv M. Patel, Douglas R. Fullen, Kei Omata, Andrzej A. Dlugosz, Scott A. Tomlins, Steven D. Billings	77
13	Morpheaform Basal Cell Carcinomas With Areas of Predominantly Single-Cell Pattern of Infiltration: Diagnostic Utility of p63 and Cytokeratin 2016 ·American Journal of Dermatopathology ·(unknown), Douglas R. Fullen, David Arps, Rajiv M. Patel, Nallasivam Palanisamy, Shannon Carskadon, Paul W. Harms	5
14	The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma 2015 ·Cancer Research ·Paul W. Harms, Pankaj Vats, Monique Verhaegen, Dan R. Robinson, Yi-Mi Wu, Saravana M. Dhanasekaran, Nallasivam Palanisamy, Javed Siddiqui, Xuhong Cao, Fengyun Su, Rui Wang, Hong Xiao, Lakshmi P. Kunju, Rohit Mehra, Scott A. Tomlins, Douglas R. Fullen, Christopher K. Bichakjian, Timothy M. Johnson, Andrzej A. Dlugosz, Arul M. Chinnaiyan	234
15	Cutaneous basal cell carcinosarcomas: evidence of clonality and recurrent chromosomal losses 2015 ·Human Pathology ·Paul W. Harms, Douglas R. Fullen, Rajiv M. Patel, (unknown), Sara C. Shalin, Linglei Ma, Benjamin A. Wood, Trevor W. Beer, Javed Siddiqui, Shannon Carskadon, Min Wang, Nallasivam Palanisamy, Gary J. Fisher, Aleodor A. Andea	20
16	Features Predicting Sentinel Lymph Node Positivity in Merkel Cell Carcinoma 2011 ·Journal of Clinical Oncology ·Jennifer Schwartz, Kent A. Griffith, Lori Lowe, Sandra L. Wong, Scott A. McLean, Douglas R. Fullen, Christopher D. Lao, James A. Hayman, Carol R. Bradford, Riley S. Rees, Timothy M. Johnson, Christopher K. Bichakjian	114
17	Phenotypic Heterogeneity among Tumorigenic Melanoma Cells from Patients that Is Reversible and Not Hierarchically Organized 2010 ·Cancer Cell ·Elsa Quintana, Mark Shackleton, Hannah R. Foster, Douglas R. Fullen, Michael S. Sabel, Timothy M. Johnson, Sean J. Morrison	446
18	Extensive Flaccid Bullae With Milia—Quiz Case 2008 ·Archives of Dermatology ·(unknown), Marcus L. Frohm, Douglas R. Fullen, Yolanda Helfrich	2
19	Asymptomatic Pedunculated Nodule on the Leg of a 75-Year-Old Man—Quiz Case 2003 ·Archives of Dermatology ·Douglas R. Fullen, Steven H. Blobstein, N. Scott McNutt	2
20	CD117 (KIT Receptor) Expression in Merkel Cell Carcinoma 2002 ·American Journal of Dermatopathology ·Lyndon D. Su, Douglas R. Fullen, Lori Lowe, Patricia Uherova, Bertram Schnitzer, Riccardo Valdez	89

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact